Suppr超能文献

发作性睡病

[Narcolepsy].

作者信息

Billiard M, Cadilhac J

出版信息

Rev Neurol (Paris). 1985;141(8-9):515-27.

PMID:2868518
Abstract

First described as a separate entity by Gelineau in 1880 and later considered as a symptom, narcolepsy has eventually been recognized as a disease on clinical and polygraphic grounds. Its prevalence stays between 0.04 and 0.06 percent. Age at onset varies from 5 to 50 with a peak in the second decade. Clinical symptoms include excessive daytime somnolence, overwhelming daytime sleep episodes, attacks of cataplexy, hypnagogic hallucinations, sleep paralysis and disturbed nocturnal sleep; sleep onset REM episodes are the main polygraphic feature. Natural history varies with the different symptoms. Excessive daytime somnolence never subsides completely. Cataplexy may disappear spontaneously. Hypnagogic hallucinations and sleep paralysis are not present in all patients and tend to be more transitory. A positive diagnosis of narcolepsy requires a minimum of one major symptom, daytime sleep episodes or cataplexy, together with documented sleep onset REM episodes. Prolonged polygraphic recordings or multiple sleep latency test are of special interest in difficult cases. Clinical variants can be grouped under three headings, incomplete, symptomatic and associated narcolepsies. The etiology of narcolepsy is not well understood. However the discovery of natural animal models of narcolepsy, mainly dogs, has prompted genetic, pharmacological and biochemical studies. The breeding of narcoleptic canine colonies has led to the evidence of a possible autosomal recessive model of inheritance in some species. Pharmacological and neurochemical analysis has shown an imbalance between monoaminergic and cholinergic mechanism. In man, extensive family studies suggest either a two-threshold multifactorial model of inheritance or a dominant mode of inheritance and immunologic studies have recently shown a strong association between HLA-DR2 and narcolepsy. Assays of CSF biogenic amines suggest a decreased bioavailability of dopamine to explain sleepiness and an imbalance between monoamines and acetylcholine to explain cataplexy. A disturbance of circadian rhythms has not been evidenced in narcoleptics. Treatment is still purely symptomatic. Amphetamines and tricyclic antidepressants have been extensively used. However they are not free of side-effects hence the need for alternative treatments.

摘要

发作性睡病于1880年由热利诺首次描述为一种独立的病症,后来被视为一种症状,最终基于临床和多导睡眠图依据被确认为一种疾病。其患病率在0.04%至0.06%之间。发病年龄从5岁到50岁不等,在第二个十年达到高峰。临床症状包括白天过度嗜睡、白天不可抗拒的睡眠发作、猝倒发作、入睡幻觉、睡眠麻痹和夜间睡眠障碍;睡眠开始时快速眼动发作是主要的多导睡眠图特征。自然病程因不同症状而异。白天过度嗜睡永远不会完全消退。猝倒可能会自发消失。入睡幻觉和睡眠麻痹并非在所有患者中都出现,且往往更具一过性。发作性睡病的阳性诊断需要至少一项主要症状,即白天睡眠发作或猝倒,以及记录到的睡眠开始时快速眼动发作。在疑难病例中,长时间的多导睡眠图记录或多次睡眠潜伏期测试尤为重要。临床变体可分为三类,即不完全性、症状性和关联性发作性睡病。发作性睡病的病因尚不完全清楚。然而,发作性睡病天然动物模型的发现,主要是狗,推动了遗传学、药理学和生物化学研究。发作性睡病犬群的繁殖已证实某些物种可能存在常染色体隐性遗传模式。药理学和神经化学分析表明单胺能和胆碱能机制之间存在失衡。在人类中,广泛的家族研究表明可能存在双阈值多因素遗传模式或显性遗传模式,并且免疫研究最近显示HLA - DR2与发作性睡病之间存在强关联。脑脊液生物胺测定表明多巴胺生物利用度降低可解释嗜睡,单胺和乙酰胆碱之间的失衡可解释猝倒。尚未在发作性睡病患者中证实昼夜节律紊乱。治疗仍然纯粹是对症治疗。苯丙胺和三环类抗抑郁药已被广泛使用。然而,它们并非没有副作用,因此需要替代治疗方法。

相似文献

1
[Narcolepsy].发作性睡病
Rev Neurol (Paris). 1985;141(8-9):515-27.
6
[Narcolepsy].发作性睡病
Rev Prat. 1996 Dec 15;46(20):2428-34.
8
[Narcolepsy with cataplexy].发作性睡病伴猝倒症
Rev Neurol (Paris). 2008 Aug-Sep;164(8-9):634-45. doi: 10.1016/j.neurol.2007.08.012. Epub 2008 Mar 4.
9
Emerging treatments for narcolepsy and its related disorders.治疗发作性睡病及其相关障碍的新方法。
Expert Opin Emerg Drugs. 2010 Mar;15(1):139-58. doi: 10.1517/14728210903559852.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验